StreetInsider.com News Articles

Nutriband adds two directors and provides development update

Fri, 30 Jan 2026 07:00:32 -0500

Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) announced the addition of two new directors and provided updates on its AVERSA™ fentanyl patch development during its annual shareholder meeting held Jan. 24 in Orlando, Florida.

The company appointed Alessandro Puddu, an Italian chartered accountant with over 10 years of audit and corporate advisory experience, and Viorica Carlig, a senior executive with a decade of leadership experience across multinational organizations, to its board of directors.

Nutriband reported several developments for its AVERSA™ fentanyl product in 2025, including strengthening its collaboration with Kindeva through an exclusive development partnership, completing commercial manufacturing process scale-up, and obtaining patent

Nutriband adds two directors and provides development update

Fri, 30 Jan 2026 07:00:32 -0500

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

Fri, 30 Jan 2026 07:00:00 -0500

ORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting, held on Jan 24, 2026 in Orlando, Florida. Details and highlights may be found below.

Addition of Two New Directors

Allesandro Puddu
Alessandro Puddu is an Italian Chartered Accountant and Statutory Auditor with over 10 years of experience in audit, corporate advisory and financial reporting for industrial groups and listed companies.

He advises companies on tax and corporate matters, company valuations, extraordinary corporate

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

Fri, 30 Jan 2026 07:00:00 -0500

Addition of Two New Directors

He advises companies on tax and corporate matters, company valuations, extraordinary corporate

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

Fri, 30 Jan 2026 07:00:00 -0500

Addition of Two New Directors

He advises companies on tax and corporate matters, company valuations, extraordinary corporate

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

Fri, 30 Jan 2026 07:00:00 -0500

Addition of Two New Directors

He advises companies on tax and corporate matters, company valuations, extraordinary corporate

Nutriband CEO issues year-end letter highlighting 2025 achievements

Wed, 31 Dec 2025 07:00:33 -0500

Nutriband Inc. (NASDAQ: NTRB) announced that CEO Gareth Sheridan published a letter to shareholders detailing company developments in 2025 and outlook for 2026.

The company agreed to sell 90% of its Pocono subsidiary to EarthVision Bio for $5 million, retaining a 10% stake in the new entity. Nutriband will maintain its interest if the entity lists on a major U.S. exchange.

In July, Nutriband issued a 25% preferred stock dividend to shareholders of record on July 25, 2025, with distribution occurring August 5. Each preferred share converts to one common share following FDA approval of the company's AVERSA Fentanyl product. Unconverted preferred

Nutriband CEO issues year-end letter highlighting 2025 achievements

Wed, 31 Dec 2025 07:00:33 -0500

Nutriband Inc. (NASDAQ: NTRB) announced that CEO Gareth Sheridan published a letter to shareholders detailing company developments in 2025 and outlook for 2026.

Nutriband CEO issues year-end letter highlighting 2025 achievements

Wed, 31 Dec 2025 07:00:33 -0500

Nutriband Inc. (NASDAQ: NTRB) announced that CEO Gareth Sheridan published a letter to shareholders detailing company developments in 2025 and outlook for 2026.

Nutriband CEO issues year-end letter highlighting 2025 achievements

Wed, 31 Dec 2025 07:00:33 -0500

Nutriband Inc. (NASDAQ: NTRB) announced that CEO Gareth Sheridan published a letter to shareholders detailing company developments in 2025 and outlook for 2026.

Nutriband CEO Publishes Letter to Shareholders

Wed, 31 Dec 2025 07:00:00 -0500

ORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The full text of the letter is below.

Dear Shareholders,

As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our appreciation to the many of you that have been with

Nutriband CEO Publishes Letter to Shareholders

Wed, 31 Dec 2025 07:00:00 -0500

Dear Shareholders,

Nutriband CEO Publishes Letter to Shareholders

Wed, 31 Dec 2025 07:00:00 -0500

Dear Shareholders,

Nutriband CEO Publishes Letter to Shareholders

Wed, 31 Dec 2025 07:00:00 -0500

Dear Shareholders,

Nutriband sells majority stake in subsidiary for $5M to EarthVision Bio

Mon, 29 Dec 2025 09:00:12 -0500

Nutriband Inc. (NASDAQ: NTRB) announced it signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million.

The transaction is expected to close on December 31, 2025. Nutriband shareholders will retain a 10% stake in EarthVision Bio following the acquisition.

EarthVision Bio develops sustainable products as alternatives to plastic, molded fiber, wood, and paper products. The company was founded by Dr. Gordon Moore, founder of Intel (NASDAQ: INTC), and Dr. Hans Franke, former board chairman for Chevron Europe.

Nutriband plans to use proceeds from the sale toward continued development of its AVERSA Fentanyl product, described

Nutriband sells majority stake in subsidiary for $5M to EarthVision Bio

Mon, 29 Dec 2025 09:00:12 -0500

Nutriband Inc. (NASDAQ: NTRB) announced it signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million.

The transaction is expected to close on December 31, 2025. Nutriband shareholders will retain a 10% stake in EarthVision Bio following the acquisition.

Nutriband plans to use proceeds from the sale toward continued development of its AVERSA Fentanyl product, described

Nutriband sells majority stake in subsidiary for $5M to EarthVision Bio

Mon, 29 Dec 2025 09:00:12 -0500

Nutriband Inc. (NASDAQ: NTRB) announced it signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million.

The transaction is expected to close on December 31, 2025. Nutriband shareholders will retain a 10% stake in EarthVision Bio following the acquisition.

Nutriband plans to use proceeds from the sale toward continued development of its AVERSA Fentanyl product, described

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio